Blog

As global drug patents continue to expire, the China generic drug market is entering a new cycle of competition and opportunity. Around 2026, the Chinese pharmaceutical industry is approaching an important milestone. Several globally important…

Liver cancer is one of the most common and deadly cancers worldwide. Because the liver can compensate for damage, early-stage disease often causes few noticeable symptoms. As a result, many people ask: what are the…

Colorectal cancer (CRC) is one of the most common malignant tumors worldwide and remains a leading cause of cancer incidence and mortality, according to the World Health Organization and the National Cancer Institute. In recent…

Against the backdrop of the ongoing restructuring of the global pharmaceutical supply chain, China is steadily emerging as a key pillar in the international drug distribution system. From the global sourcing of innovative medicines, to…

In the context of increasingly stringent global pharmaceutical regulations, choosing a licensed Pharmaceutical Distributor in Hong Kong with verified wholesale and export qualifications means selecting a long-term partner with regulatory compliance, cross-border execution capabilities, and…

In 1852, French physician Duchenne described boys with progressive muscle weakness whose enlarged calves were replaced by fat and fibrous tissue, leading to death from respiratory or cardiac complications in adolescence or early adulthood. The…

In today’s increasingly competitive global pharmaceutical landscape, choosing a reputable pharmaceutical wholesaler has become a critical strategic decision for pharmaceutical companies, healthcare institutions, and medical traders seeking sustainable long-term growth. A reliable partner not only…

Lung cancer remains the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Thanks to advances in molecular pathology, its treatment has shifted from traditional chemotherapy…

Before the advent of targeted therapy, ALK-positive advanced non-small cell lung cancer (NSCLC) typically progressed rapidly, with a high incidence of brain metastases and limited median survival. Treatment strategies primarily relied on passive control through…

Epidermal growth factor receptor EGFR–targeted drugs represent a cornerstone in the treatment of advanced non–small cell lung cancer (NSCLC) harboring EGFR gene mutations. EGFR mutations are a major category of lung cancer biomarkers. NSCLC is…

In recent years, rare disease treatment has rapidly risen from a niche medical issue to one of the most active core areas of global pharmaceutical innovation. Advances in gene sequencing technology, breakthroughs in cell and…

In recent years, immune checkpoint inhibitors have revolutionized the field of anti-tumor treatment, among which PD-1 (programmed death protein 1) monoclonal antibodies have become a core therapeutic option for multiple advanced tumors due to their…